

Harnessing the EHR to Streamline Workflow & Reporting

Kristen Whelchel, PharmD, CSP | Cori Edmonds, PharmD, BCPS, CSP | Bridget Lynch, PharmD, MS
Vanderbilt University Medical Center, Department of Pharmaceutical Services

CONCLUSION

- SmartForms streamlined workflow
- Duplicative documentation decreased
- Reporting and outcomes monitoring capabilities improved

PURPOSE

To streamline specialty pharmacist documentation and reporting capabilities by using SmartForms in routine electronic health record documentation for patients with Hepatitis C.

METHODS



Quality Improvement Project
Vanderbilt Specialty Pharmacy
Hepatology Clinic

Evaluate current workflow and documentation practices



Design and build SmartForms to capture discrete data for reporting within current documentation

Build a dashboard for patient monitoring and reporting using SmartForms data

RESULTS



Treatment Monitoring Dashboard



Pre-Treatment SmartForm

HCV Type: Acute, Chronic, Unspecified

HCV Genotype: 1, 1A, 1B, 2, 3, 4, 5, 6, Unknown

HCV Baseline Viral Load (IU/mL):

Date of Baseline Viral Load:

HCV Prior Treatment Status: Naive, Experienced, Reinfected, Unknown

HCV Baseline RAV: Yes, No, Unknown, Not Applicable, Not Available

Post-Transplant Status: Not Applicable, Liver, Kidney, Heart, Lung

Liver Staging: Non-cirrhotic, F0-F1, F1-F2, F2-F3, F3-F4, F0, F1, F2, F3, F4

Text Generation

Create Note: Specialty Assessment 1

My Note: VUMC VSP HCV TREATMENT DETAILS, VUMC VSP HCV DDI ASSESSMENT

Summary:

HCV Initial Therapy Teaching

Medication Education: HCV Counseling Type

Person(s) present for education: Ms. Kate Id Validate

HCV TREATMENT DETAILS

I have reviewed the patient's chart. The salient information is as follows: Kate Id Validate has a history of HCV Genotype 1A infection, is treatment Naive with a base line viral load of 120,000 IU/mL on 8/1/2022. she was previously treated with No value filed. she has Non-cirrhotic fibrosis and a CTP score of No value filed. HCC status: No history of HCC Status post Liver transplant.

Final Chart Note

HCV Therapy Monitoring: Eplusa week 3/24

HPI: I have reviewed the patient's chart. The salient information is as follows: has a history of HCV Genotype 1A infection and was treatment Naive prior to current HCV therapy start. he has F4 fibrosis and a CTP score of 7B.

HCV Treatment Details: sofosbuvir-velpatasvir 400-100mg (Eplusa) Tablets for 24 weeks
Start date: 6/1/2022
Anticipated EOT: 11/15/2022
Anticipated SVR12: 2/8/2022

HCV Treatment Status: Patient is currently at week 3 on treatment. End of treatment date has been updated: 11/15/2022
Updated SVR12 due date has been noted: 2/8/2023

Adherence: has missed 3 doses of medication since starting HCV therapy. Verified by patient report. Patient developed nausea/vomiting which required hospital stay. He reports missing or vomiting doses on 6/16-6/18. He restarted on Sunday 6/19/22. He is tolerating well at this time. He also missed Vemlidy doses those same days.

Side Effects: The patient is experiencing the following side effects: nausea and vomiting.

Side Effect Notes: He took ondansetron last week but started it after N/V began and felt it was too late for it to help. His nephrologist referred him to ED. Patient reports he had an issue like this once before a while back. The only explanation at this time was diverticulitis episode. He is doing better now.

HCV Therapy Monitoring: Patient's current treatment status- On treatment.